Skip to main content
Clinical Trials/NCT04775901
NCT04775901
Unknown
Not Applicable

Application of Three-Dimensionally Printed Navigational Template in Percutaneous Transthoracic Lung Biopsy: A Prospective, Randomized, Controlled, Noninferiority Trial

Shanghai Pulmonary Hospital, Shanghai, China1 site in 1 country150 target enrollmentNovember 25, 2020
ConditionsLung Neoplasms

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lung Neoplasms
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Enrollment
150
Locations
1
Primary Endpoint
Diagnostic yield of percutaneous transthoracic fine-needle aspiration
Last Updated
5 years ago

Overview

Brief Summary

This is a prospective, randomized, controlled study to evaluate the diagnostic yield and safety of three-dimensionally printed navigational template in percutaneous transthoracic lung biopsy.

Detailed Description

The feasibility of three-dimensionally printed navigational template-guided percutaneous transthoracic fine-needle aspiration was validated by a phase I study. To further investigate the non-inferiority of navigational template-guided lung biopsy to conventional CT-guided modality in terms of diagnostic yield, this prospective, randomized, controlled, noninferiority trial was conducted.

Registry
clinicaltrials.gov
Start Date
November 25, 2020
End Date
December 31, 2023
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Responsible Party
Principal Investigator
Principal Investigator

Chang Chen

Prof. Dr.

Shanghai Pulmonary Hospital, Shanghai, China

Eligibility Criteria

Inclusion Criteria

  • A. CT confirmed peripheral lung lesion;
  • B. Nodule size larger than or equal to 30 mm;
  • C. Scheduled for percutaneous transthoracic fine-needle aspiration;
  • D. Percutaneous transthoracic lung biopsy was conducted at supine or partially lateral decubitus;
  • E. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2;
  • F. Written informed consent provided.

Exclusion Criteria

  • A. Biopsy needle insertion route impeded by skeletal structures;
  • B. Lesion within 3 cm above diaphragmatic dome;
  • C. Insertion route longer than the biopsy needle;
  • D. Lung biopsy needed to be conducted at vertically lateral decubitus;
  • E. Any contraindication of percutaneous transthoracic lung biopsy;
  • F. Women who are pregnant or in the period of breastfeeding.

Outcomes

Primary Outcomes

Diagnostic yield of percutaneous transthoracic fine-needle aspiration

Time Frame: Three to four working days post-biopsy were needed to establish the diagnosis of the cytological specimens acquired by fine-needle aspiration.

A percutaneous transthoracic fine-needle aspiration procedure was considered diagnostic if a malignant or specific benign diagnosis of the lesion was made. The ratio of diagnostic cases to all the participants who received the corresponding biopsy was considered as diagnostic yield.

Secondary Outcomes

  • Radiation exposure(15 mins post biopsy)
  • Diagnostic sensitivity of percutaneous transthoracic fine-needle aspiration(If an eventual diagnosis was attained by means of follow-up, a 12-month assessment was needed.)
  • Complication rate(Real-time complication post biopsy indicates those recognized by the immediate CT scan, while delayed complication indicates those recognized by radiograph taken 4-6 hours post biopsy.)
  • Procedural duration(15 mins post biopsy)

Study Sites (1)

Loading locations...

Similar Trials